SNCA Recombinant Monoclonal Antibody

說(shuō)明書

中文名稱：

SNCA重組抗體
貨號(hào)：

CSB-RA021912MA1HU
規(guī)格：

￥1320
圖片：
IHC image of CSB-RA021912MA1HU diluted at 1:100 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB.

IHC image of CSB-RA021912MA1HU diluted at 1:100 and staining in paraffin-embedded human glioma cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB.

Immunofluorescence staining of SH-SY5Y cell with CSB-RA021912MA1HU at 1:30, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG(H+L).

Overlay Peak curve showing SH-SY5Y cells stained with CSB-RA021912MA1HU (red line) at 1:100. The cells were fixed in 4% formaldehyde (15min) and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum was Incubated to block non-specific protein-protein interactions followed by the antibody (1μg/1*10⁶cells) for 45 min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1/200 dilution for 35 min at 4°C. Isotype control antibody (green line) was mouse IgG1 (1μg/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品描述：

CSB-RA021912MA1HU SNCA重組單克隆抗體是針對(duì)α-突觸核蛋白（SNCA）開發(fā)的高特異性科研工具，該靶點(diǎn)作為突觸前神經(jīng)遞質(zhì)調(diào)控的關(guān)鍵分子，在帕金森病、路易體癡呆等神經(jīng)退行性疾病的病理機(jī)制中起重要作用。本產(chǎn)品經(jīng)過(guò)多種平臺(tái)嚴(yán)格驗(yàn)證，可高效應(yīng)用于ELISA檢測(cè)，并在免疫組化（IHC）、免疫熒光（IF）和流式細(xì)胞術(shù)（FC）分析中展現(xiàn)優(yōu)異性能，推薦使用稀釋度范圍為1:20-1:200。實(shí)驗(yàn)數(shù)據(jù)顯示，該抗體能清晰顯示腦組織切片中路易小體的特異性染色，精準(zhǔn)定位細(xì)胞模型中的SNCA蛋白聚集形態(tài)，同時(shí)支持流式細(xì)胞術(shù)定量分析體外培養(yǎng)樣本的蛋白表達(dá)水平。其高靈敏度和低交叉反應(yīng)性特點(diǎn)，使其適用于神經(jīng)退行性疾病分子機(jī)制研究、病理模型蛋白異常聚集分析以及體外藥物篩選實(shí)驗(yàn)中靶標(biāo)動(dòng)態(tài)監(jiān)測(cè)等科研場(chǎng)景。產(chǎn)品采用重組表達(dá)技術(shù)生產(chǎn)，具有批次間高度一致性，為神經(jīng)科學(xué)領(lǐng)域提供穩(wěn)定可靠的研究工具。
Uniprot No.：

P37840
基因名：

SNCA
別名：

Alpha synuclein antibody; Alpha-synuclein antibody; Alpha-synuclein; isoform NACP140 antibody; alphaSYN antibody; MGC105443 antibody; MGC110988 antibody; MGC127560 antibody; MGC64356 antibody; NACP antibody; Non A beta component of AD amyloid antibody; Non A4 component of amyloid antibody; Non A4 component of amyloid precursor antibody; Non-A beta component of AD amyloid antibody; Non-A-beta component of alzheimers disease amyloid ; precursor of antibody; Non-A4 component of amyloid precursor antibody; Non-A4 component of amyloid; precursor of antibody; OTTHUMP00000218549 antibody; OTTHUMP00000218551 antibody; OTTHUMP00000218552 antibody; OTTHUMP00000218553 antibody; OTTHUMP00000218554 antibody; PARK 1 antibody; PARK 4 antibody; PARK1 antibody; PARK4 antibody; Parkinson disease (autosomal dominant; Lewy body) 4 antibody; Parkinson disease familial 1 antibody; SNCA antibody; Snca synuclein antibody; Snca synuclein; alpha (non A4 component of amyloid precursor) antibody; SYN antibody; Synuclein alpha antibody; Synuclein alpha 140 antibody; Synuclein; alpha (non A4 component of amyloid precursor) antibody; SYUA_HUMAN antibody
反應(yīng)種屬：

Human
免疫原：

Recombinant Human SNCA protein
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Mouse IgG2a
純化方式：

Affinity-chromatography
克隆號(hào)：

10E5
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC, IF, FC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200
IF	1:20-1:200
FC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Flow cytometry (FC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis. Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. This chaperone activity is important to sustain normal SNARE-complex assembly during aging. Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity.
基因功能參考文獻(xiàn)：
1. Results provide evidence of the role of SNCA in opiate dependence PMID: 21309955
2. The molecular basis and clinical relevance of statistically decreased alphaSyn pathology in schizophrenic brain versus aged controls is unknown and needs further elucidation as will be necessary for its incidence and relevance in chronic affective disorders. PMID: 19198857
3. Elevated levels of insoluble alpha-Syn seen in brains of patients with Parkinson's and dementia are higher than that of Parkinson brains, for insoluble and insoluble/soluble alpha-Syn, respectively, with a highly significant difference between the two groups. PMID: 20599975
4. Data suggest that the key molecular scaffold most effective in inhibiting and destabilizing self-assembly by alphaS requires: (i) aromatic elements for binding to the alphaS monomer/oligomer and (ii) vicinal hydroxyl groups present on a single phenyl ring. PMID: 21443877
5. [review] The role of alpha-syn is summarized in synaptic vesicle recycling, neurotransmitter synthesis and release and synaptic plasticity, as well as the possible relevance between the loss of normal alpha-syn functions in disease conditions. PMID: 21167933
6. Age-related accumulation of neuromelanin might induce alpha-synuclein over-expression and thereby make dopamine neurons more vulnerable to injuries. PMID: 21461961
7. alpha-Synuclein function in promoting cell proliferation is associated with its microtubule assembly activity with the functional domain localized in its carboxyl-terminal part. PMID: 21331461
8. Association ofalpha-synuclein with Rab attachment receptor protein and soluble sensitive factor attachment receptors (SNAREs) highlights a key role for membrane transport defects in alpha-synuclein-mediated pathology. PMID: 21439320
9. Our result strongly indicates that Parkinson's disease, induced by alpha-SYN mutation, is evoked by deregulation of the AKT-signaling cascade. PMID: 21474915
10. Genetic mutations in the alpha-synuclein gene can lead to Parkinson's disease, but even in these patients, age-dependent physiological changes or environmental exposures appear to be involved in disease presentation. PMID: 21238487
11. Our results imply that CSF alpha-synuclein is currently unsuitable as biomarker to differentiate between PD and AP. PMID: 21236518
12. [review] Presynaptic function is implicated in the function/dysfunction of alpha-synuclein, the first gene shown to contribute to Parkinson's disease (PD), in this review of genetic models of PD. PMID: 20969957
13. In the Caucasian patient-control series examined, risk for Parkinson disease is influenced by variation in SNCA and tau proteins but not glycogen synthase kinase (GSK)beta3. PMID: 21159074
14. Overexpression of alpha-Syn transgene alters dopamine efflux and dopamine D2 receptor modulation of corticostriatal glutamate release at a young age in mice. PMID: 21488084
15. An artificial microRNA-embedded human SNCA silencing vector is expressed lacks toxicity in rat PC12 cells in which rat SNCA is not silenced and has reduced toxicity in human SH-SY5Y cells in which hSNCA is silenced. PMID: 21338582
16. Patients with multiple system atrophy may have a cerebrospinal fluid environment particularly favorable for alpha-synuclein fibril formation. PMID: 21215793
17. Iron up-regulates alpha-synuclein and induces aggregation through the predicted iron responsive element (IRE) in the 5'-untranslated region (UTR) of human alpha-synuclein mRNA. PMID: 20383623
18. an association of the two SNPs in 4q22/SNCA with the age of onset of Parkinson's disease PMID: 21044948
19. Findings suggest that alpha-synuclein pathology is associated with Tar DNA-binding protein-43 accumulation in Lewy body disease. PMID: 20669025
20. Attenuation of nigral SNCA pathology and dopaminergic neurodegeneration by inhibition of NADPH oxidase and iNOS supports a causative relation between inflammation-mediated SNCA pathologic alterations and chronic dopaminergic neurodegeneration. PMID: 21245015
21. Data describe spontaneous accumulation of hyperphosphorylated tau in striata of a mouse model of Parkinsonism, which overexpresses human a-Synuclein under the PDGF promoter. PMID: 21453448
22. Direct replication of single nucleotide polymorphisms (SNPs) within SNCA and BST1 confirmed these two genes to be associated with the Parkinson's Disease in the Netherlands. PMID: 21248740
23. Transgenic alpha-synuclein localizes to the mitochondrial membranes under conditions of proteasomal inhibitory stress; this localization coincides with selective age-related mitochondrial complex I inhibition. PMID: 20887775
24. Synphilin-1 inhibits alpha-synuclein degradation by the proteasome. PMID: 21103907
25. From crystal structures of fusions between maltose-binding protein and four segments of alpha-synuclein, the study traces a virtual model of the first 72 residues of alpha -synuclein. PMID: 21462277
26. In transgenic mice, the norepinephrine systems may be more vulnerable than dopamine systems to toxic effects of aberrant alpha-synuclein; this is in line with the major damage to the noradrenaline system that occurs in patients with Parkinson's disease. PMID: 19152986
27. In patients diagnosed with dementia with Lewy bodies, lower cerebrospinal fluid alpha-synuclein levels may perhaps be associated with lower cognitive performance, in comparison to patients who are diagnosed with Alzheimer's disease. PMID: 20847452
28. A novel function for BAG5 as a modulator of CHIP E3 ubiquitin ligase activity with implications for CHIP-mediated regulation of alpha-syn oligomerization. PMID: 21358815
29. Single-nucleotide polymorphisms in SNCA (rs356219; P = 5.5 x 10(-4) ) is significantly associated with Parkinson's disease PMID: 21425343
30. alpha-Synuclein thus exerts a primary and direct effect on the morphology of an organelle long implicated in the pathogenesis of Parkinson disease. PMID: 21489994
31. evidence that alpha-synuclein is a cellular ferrireductase, responsible for reducing iron (III) to bio available iron (II) PMID: 21249223
32. study found a significant association between the NACP-Rep1 length polymorphism and Beck Depression Inventory (BDI) score; analysis revealed no further association between the In4 polymorphism or between the mRNA expression of SNCA and the BDI score PMID: 21271299
33. mechanistic insights on the role alpha-synuclein in modulating neurodegenerative phenotypes by regulation of Akt-mediated cell survival signaling in vivo PMID: 21304957
34. overexpression of alpha-syn may cause mitochondrial defects in dopaminergic neurons of the substantia nigra through an association with adenylate translocator and activation of mitochondria-dependent cell death pathways PMID: 21310263
35. data demonstrate an elevated state of tauopathy in striata of the A53T alpha-Syn mutant mice, suggesting that tauopathy is a common feature of synucleinopathies PMID: 21445308
36. REVIEW: alpha-Synuclein in Parkinson disease and other neurodegenerative disorders PMID: 21342025
37. Data suggest that membrane lipid modification in oligodendroglial cells containing SUMO-1 promotes the formation of alpha-synuclein inclusion bodies resembling protein aggregates in neurodegenerative disease. PMID: 20725866
38. Data suggest that low SMN levels are associated with significantly lower alpha-synuclein expression, and that alpha-synuclein may be a genetic modifier or biomarker of spinal muscular atrophy. PMID: 20640532
39. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes PMID: 21412942
40. Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination PMID: 21466165
41. analysis of the mechanism of membrane permeabilization by oligomeric alpha-synuclein PMID: 21179192
42. the relation between membrane physical properties and AS binding affinity and dynamics that presumably define protein localization in vivo and, thereby, the role of AS in the physiopathology of Parkinson disease. PMID: 21330368
43. MMP3 digestion of alpha-synuclein in DA neurons plays a pivotal role in the progression of Parkinson disease through modulation of alpha-synuclein in aggregation, Lewy body formation, and neurotoxicity PMID: 21330369
44. Coordination features and affinity of the Cu(2)+ site in the alpha-synuclein protein of Parkinson's disease PMID: 21319811
45. This study confirms the association between PD and both SNCA SNPs and the H1 MAPT haplotype. PMID: 21391235
46. In this work Cu(ii) coordination to peptide fragments encompassing residues 45-55 of synuclein alpha has been exhaustively characterized, including systems containing the inherited mutations E46K and A53T, as model peptides of the His-50 site. PMID: 21212878
47. results support the hypothesis that WT and A53T alpha-synuclein has an important role in the initiation and maintenance of inflammation in Parkinson's disease PMID: 21255620
48. The combined data indicate that the A30P mutation does not cause changes in the number, location and overall arrangement of beta-strands in amyloid fibrils of alpha-synuclein. PMID: 21280130
49. Data suggest that mutations in alpha-synuclein may impair specific functional domains, leaving others intact. PMID: 21272100
50. Single locus analysis showed that G/G SNCA and H1/H1 MAPT risk genotypes were over-represented in patients with Parkinson disease compared with controls PMID: 21054681
顯示更多

收起更多
相關(guān)疾病：

Parkinson disease 1, autosomal dominant (PARK1); Parkinson disease 4, autosomal dominant (PARK4); Dementia Lewy body (DLB)
亞細(xì)胞定位：

Cytoplasm. Membrane. Nucleus. Cell junction, synapse. Secreted.
蛋白家族：

Synuclein family
組織特異性：

Highly expressed in presynaptic terminals in the central nervous system. Expressed principally in brain.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 11138

OMIM: 127750

KEGG: hsa:6622

STRING: 9606.ENSP00000338345

UniGene: Hs.21374

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human